Status:
COMPLETED
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
Lead Sponsor:
University Hospital, Brest
Conditions:
Carcinoma, Non-Small-Cell Lung
Immunotherapy
Eligibility:
All Genders
18+ years
Brief Summary
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed NSCLC PD- L1 TPS ≥ 50% stage III and IV WHO performance status of 0, 1 or 2 adequate organ function
Exclusion
- previous EGFR or ALK aberrations positive test for hepatitis B or C virus indicating acute or chronic infection known history of testing positive for human immunodeficiency virus (HIV) severe, uncontrolled autoimmune disease.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 2 2019
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT05321212
Start Date
January 2 2019
End Date
March 2 2019
Last Update
April 11 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609
2
CHIC de QUIMPER
Quimper, France, 29000